New drug combo shows promise for MDS and AML

NCT ID NCT00392353

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two drugs, vorinostat and azacitidine, together in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal is to find the best dose and see if the combination is safe and effective. About 135 participants will take part in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

vorinostat and azacitidine

What this could lead to

If successful, this combination could offer a new treatment option for patients with myelodysplastic syndrome or acute myeloid leukemia.

What could go wrong

This is an early-phase trial, so the combination may not prove effective or may cause significant side effects. Results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute erythroid leukemia acute megakaryoblastic leukemia acute myeloid leukemia acute myeloid leukemia with multilineage dysplasia chronic myelomonocytic leukemia myelodysplastic syndrome myelodysplastic syndrome with excess blasts myelodysplastic syndrome with ring sideroblasts myelodysplastic syndrome with single lineage dysplasia Myelodysplastic Syndromes refractory anemia with excess blasts in transformation therapy related acute myeloid leukemia and myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ERYTHROID LEUKEMIA ACUTE MEGAKARYOBLASTIC LEUKEMIA ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME CHRONIC MYELOMONOCYTIC LEUKEMIA MYELODYSPLASTIC SYNDROME MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS MYELODYSPLASTIC SYNDROME WITH RING SIDEROBLASTS RECURRENT ADULT ACUTE MYELOID LEUKEMIA REFRACTORY ANEMIA

Contacts and locations

Show contact details

Locations

Montefiore Medical Center - Moses Campus

The Bronx, New York, 10467, United States
Montefiore Medical Center-Weiler Hospital

The Bronx, New York, 10461, United States
Mount Sinai Hospital

New York, New York, 10029, United States
NYP/Weill Cornell Medical Center

New York, New York, 10065, United States
North Shore University Hospital

Manhasset, New York, 11030, United States
University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637, United States
University of Maryland/Greenebaum Cancer Center

Baltimore, Maryland, 21201, United States